Genzyme’s Announces Launch of Expression of Hope III Art Exhibit
Genzyme, a Sanofi company, announced today that selected artwork from Expression of Hope III will be featured through a travelling exhibit and online gallery. Expression of Hope is a global disease awareness program featuring works of art created by the community of people affected by lysosomal storage disorders (LSD). This unique program encourages anyone affected by an LSD to create and submit a work of art that expresses their experiences of living with these rare, inherited diseases.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150520005144/en/
The 25 piece Expression of Hope III exhibit will open today at Genzyme Center in Cambridge, Mass. The exhibit will travel to patient meetings and conferences around the world in 2015 and 2016. Initial exhibits include the National Niemann-Pick Disease Foundation family conference in Chicago, Illinois, the Niemann-Pick Disease Group – UK Family Conference in the United Kingdom, and the Global Genes “Tribute to Champions of Hope” Gala in California. Future exhibits are currently being planned for the Asia-Pacific region and Latin America. All of the 168 artwork submissions, including the 25 exhibit selections, can be viewed at www.expressionofhope.com.
Working in collaboration with patient advocacy organizations around the world, Expression of Hope III received submissions from artists of all ages and artistic ability, including family members, friends and healthcare workers from over 20 countries. The exhibit artwork was selected by a panel of professional artists from the Massachusetts area, including Lesley University’s Expressive Therapies program, the DeCordova Museum, Massachusetts College of Art and the Rocky Neck Arts Colony. This is the third Expression of Hope campaign, with nearly 500 artwork submissions received since the program first launched in in 2006.
“Artistic expression transcends barriers created by geography, language, physical ability and age,” said Genzyme’s Head of Rare Diseases, Richard Peters, M.D., Ph.D. “By sharing these reflections of the human spirit with the world, the Expression of Hope artists challenge and motivate thousands of people to better understand the experience of living with an LSD.”
Lysosomal storage disorders, also known as lipid storage disorders, are a group of inherited metabolic conditions in which fatty materials (lipids) accumulate in various cells and tissues in the body. People with these disorders either do not produce enough of an enzyme required to break down (metabolize) lipids, or they produce enzymes that do not work properly. Over time, the build-up of lipids can lead to cellular and tissue damage, particularly in the brain, peripheral nervous system, liver, spleen, and bone marrow. Examples of LSDs include Gaucher, Fabry, Pompe, MPS and Niemann-Pick diseases.
About Expression of Hope
Expression of Hope is a global program of inspiration and awareness featuring works of art by the lysosomal storage disorder community. In collaboration with LSD patient organizations around the world, Genzyme launched the Expression of Hope program in 2006 to give those impacted by lysosomal storage disorders (LSDs) the opportunity to raise awareness of these rare genetic diseases. More than 100 patients and caregivers expressed their unique stories through their original pieces of artwork. Building on that initial success, Genzyme launched the second Expression of Hope program in 2009, and once again the global community responded with enthusiasm, creativity and insight. Our third Expression of Hope program further reinforces the commitment of individuals affected by lysosomal storage disorders to building awareness and expressing their unique stories through art. www.Expressionofhope.com
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Sorry. No data so far.